Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cepheid

- PMLiVE

AZ’s Onglyza may increase mortality, says FDA

Kombiglyze also under scrutiny

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

Eli Lilly HQ

Pfizer and Lilly restart tanezumab pain trials

FDAlifts clinical block on late-stage studies of the novel painkiller

- PMLiVE

R&D productivity takes off

Approvals of NMEs reach heights last seen in the mid-1990s

- PMLiVE

US approval for Astellas’ new antifungal drug Cresemba

Japanese firm co-markets the azole antifungal agent with Basilea

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

FDA launches drug shortages mobile app

USregulator offers the public and HCPs Android and iPhone versions of the app

- PMLiVE

Apotex latest to file Neupogen biosimilar in the US

White blood cell stimulator could be on the market this year

- PMLiVE

FDA outlines its plans to simplify DTC ads for consumers

Hopes customer-friendly terminology will aid healthcare decisions

- PMLiVE

Hamburg to resign as FDA commissioner

She has held the role for nearly six years

- PMLiVE

Merck’s hep C drug no longer a ‘breakthrough’

FDA rescinds designation for grazoprevir/elbasvir due to approval of other treatments

- PMLiVE

FDA approves first continuous glucose monitoring app

Clears remote blood sugar monitor Dexcom Share

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links